Spontaneous regression of transverse colon cancer: a case report
© The Author(s). 2017
Received: 10 January 2017
Accepted: 2 May 2017
Published: 10 May 2017
Spontaneous regression (SR) of many malignant tumors has been well documented, with an approximate incidence of one per 60,000–100,000 cancer patients. However, SR of colorectal cancer (CRC) is very rare, accounting for less than 2% of such cases. We report a case of SR of transverse colon cancer in an 80-year-old man undergoing outpatient follow-up after surgical treatment of early gastric cancer. Colonoscopy (CS) revealed a Borrmann type II tumor in the transverse colon measuring 30 × 30 mm. Because the patient underwent anticoagulant therapy, we did not perform a biopsy at that time. A second CS was performed 1 week after the initial examination and revealed tumor shrinkage to a diameter of 20 mm and a shift to the Borrmann type III morphology. Biopsy revealed a poorly differentiated adenocarcinoma. One week after the second CS, we performed a partial resection of the transverse colon and D2 lymph node dissection. Histopathology revealed inflammatory cell infiltration and fibrosis from the submucosal to muscularis propria layers in the absence of cancer cells, leading to pathological staging of pStage 0 (T0N0). The patient had an uneventful recovery, and CS performed at 5 months postoperatively revealed the absence of a tumor in the colon and rectum. The patient continues to be followed up as an outpatient at 12 months postoperatively, and no recurrence has been observed.
KeywordsSpontaneous regression Colon cancer Immune response
Spontaneous regression (SR) of a malignant tumor is defined as a partial or complete disappearance of a tumor without treatment or in response to a treatment that is considered inadequate to exert a significant influence on neoplastic disease . SR has been well documented for many types of cancer, with an overall estimated incidence of approximately one per every 60,000–100,000 cancer patients . However, SR of colorectal cancer (CRC) is very rare, accounting for less than 2% of such cases . Here, we report a case of SR of transverse colon cancer in which we could morphologically observe the course of shrinkage.
An 80-year-old man with a previous history of interstitial pneumonia, paroxysmal atrial fibrillation (pAf), and hypertension was undergoing outpatient follow-up after surgical therapy for early gastric cancer. He was not receiving chemotherapy and immunotherapy and was orally taking apixaban only.
One week after the second CS, the patient underwent the surgery. Because, intraoperatively, we could not find out the tumor at the preoperative marking site, we resected the transverse colon at the distance of 5 cm from the marking and dissected the marginal and intermediate lymph nodes. Consequently, partial surgical resection of the transverse colon and D2 lymph node dissection were performed.
The final pathological staging was pStage 0 (T0N0) according to the TNM classification.
The patient had an uneventful recovery. CS performed 5 months postoperatively revealed an absence of tumors in the colon and rectum, and his CA19-9 level decreased to within the normal range. The patient remains under outpatient follow-up at 12 months postoperatively, with no observed recurrence.
SR of cancer is one of the most remarkable phenomena in medicine. Thus far, SR is reported in virtually all types of human cancer, with the highest numbers of reported cases among patients with neuroblastoma, renal cell carcinoma, malignant melanoma, and lymphoma/leukemia. In contrast, SR of CRC is extremely rare . A review of cases involving SR of CRC between 1900 and 2005 confirmed only 11 such cases, at least with regard to the primary tumor .
Five cases of SR of primary CRC reported since 2006
Regarding the surgical procedure, SR of cancer can be proven only in the excised specimens; thus, we suggest that it is necessary to resect the primary cancer with secured enough margins, and the dissection of lymph nodes should correspond to preoperative staging, even if there is SR of colon cancer.
Although many of the mechanistic details of SR of cancer remain unclear, the following have been suggested as factors: immunological, endocrine, metabolic, surgical, and postoperative events; elimination of a carcinogen or antigen; inhibition of angiogenesis; tumor necrosis; changes in oncogenes, growth factors, or cytokines; genetic and epigenetic factors; induction of benign differentiation and apoptosis; and psychological factors [3, 10]. Previous reports have described a central role for immune-mediated host responses in SR of solid tumors; for example, SR has been observed in many patients with carcinomas that contained significantly higher numbers of infiltrating immune cells (e.g., activated CD3+ T cells, NK cells, antigen presenting cells) than the non-regressing controls .
Although CRCs have long been considered poorly immunogenic, some CRCs exhibit marked inflammatory cell infiltration. In a multivariate analysis of factors affecting rectal cancer, Jass et al. previously reported that conspicuous lymphocytic infiltration along the invasive margin was an independent prognostic factor for improved survival . Ropponen et al. reported that according to both univariate and multivariate analyses, the presence of tumor-infiltrating lymphocytes (TILs) is a significant predictor of improved overall and recurrence-free survival among patients with CRC . Furthermore, CRCs with the high microsatellite instability (MSI-H) phenotype, which accounts for approximately 15% of sporadic CRCs, tend to associate with high numbers of TIL; accordingly, this phenotype is currently considered a clinically useful predictor of a good outcome . Unfortunately, our patient refused to undergo examination for MSI status; thus, MSI status of this case was unknown.
CD8+ T cells have traditionally been considered the key factor in effective antitumor immunity. Because most tumors do not express major histocompatibility complex (MHC) class II, the potential antitumor-protective role of CD4+ T cells, which bind MHC class II molecules on target cells, has been less obvious. Nevertheless, Overwijk found that each person’s naive CD4+ T cells spontaneously responded to neoepitopes or peptides derived from cancer proteins encoded by mutated genes. Furthermore, these neoepitope-specific CD4+ T cells could directly induce cancer cell death and tumor regression by altering the tumor-promoting functions of cells in the surrounding tumor microenvironment .
In addition, MSI-H tumor cells have been shown to generate and present novel tumor-specific frameshift-derived neopeptides (FPS) ; these appear to affect the immune responses mediated by neoepitope-specific CD4+ T cells. In particular, pronounced CD4+ T cell infiltration has been observed in MSI-H CRCs that lack MHC class II expression . In our case, although few infiltrating CD8+ T cells were observed, large numbers of CD4+ T cells were present along the cancer stroma in both biopsy and excised specimens and dissected lymph nodes. Our case suggests an association between SR of CRC and an adaptive immunological response to the carcinoma that is mediated particularly by CD4+ T cells.
In conclusion, we have presented our experience with a rare case of SR of a transverse colon cancer. Our findings suggest that this SR may have been attributable to an immune-mediated antitumor response, mainly mediated by CD4+ T cells. SR induction may involve multiple mechanisms that, in some cases, are intricately linked. Accordingly, it may be difficult to determine the predominant mechanism in a particular case. However, we believe that the elucidation of SR-related mechanisms will lead to improved immunotherapy and cancer prevention methods.
We are grateful to Ms. Smith for carefully proofreading the manuscript.
AH helped to draft the manuscript of the pathological findings. KN, HS, SH, KK, and AT conceived the case report and helped draft the manuscript. All authors have read and approved the final manuscript.
The authors declare that they have no competing interests.
Consent for publication
We have obtained the consent and attached the file to this manuscript as a Additional file 1.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Stewart FW. Experiences in spontaneous regression of neoplastic disease in man. Tex Rep Biol Med. 1952;10:239–53.PubMedGoogle Scholar
- Jerry LM, Challis EB. Oncology. In: Rakel RE, editor. Textbook of family practice. 3rd ed. 1987. p. 1061–81.Google Scholar
- Challis GB, Stam HJ. The spontaneous regression of cancer. A review of cases from cases from 1900 from 1987. Acta Oncol. 1990;29:545–50.View ArticlePubMedGoogle Scholar
- Papac RJ. Spontaneous regression of cancer: possible mechanisms. In Vivo. 1998;12:571–8.PubMedGoogle Scholar
- Du C, Wang Y. The immunoregulatory mechanisms of carcinoma for its survival and development. J Exp Clin Cancer Res. 2011;30:1.View ArticleGoogle Scholar
- Sakamoto S, Fu K, Kobayashi O, Matsuyama S, Miyazaki A, Ogura K, et al. Spontaneous complete regression of a rectal cancer. Endoscopy. 2009;41:910–2.View ArticlePubMedGoogle Scholar
- Shimizu H, Kochi M, Kaiga T, Mihara Y, Fujii M, Takayama T. A case of spontaneous regression of advanced colon cancer. Anticancer Res. 2010;30:2351–3.PubMedGoogle Scholar
- Sekiguchi M, Ito K, Matsuhashi N. Spontaneously disappearing colon cancer. Dig Endosc. 2013;25:88–9.View ArticlePubMedGoogle Scholar
- Kihara K, Fujita S, Ohshiro T, Yamamoto S, Sekine S. Spontaneous regression of colon cancer. Jpn J Clin Oncol. 2015;45:111–4.View ArticlePubMedGoogle Scholar
- Cole WH. Efforts to explain spontaneous regression of cancer. J Surg Oncol. 1981;17:201–9.View ArticlePubMedGoogle Scholar
- Abdelrazeq AS. Spontaneous regression of colorectal cancer: a review of cases from 1900 to 2005. Int J Colorectal Dis. 2007;22:727–36.View ArticlePubMedGoogle Scholar
- Jass JR, Love SB, Northover JMA. A new prognostic classification of rectal cancer. Lancet. 1987;1:1303–6.View ArticlePubMedGoogle Scholar
- Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E, Kosma VM. Prognostic value of tumor-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 1997;182:318–24.View ArticlePubMedGoogle Scholar
- Smyrk TC, Watson P, Kaul K, Lynch HT. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417–22.View ArticlePubMedGoogle Scholar
- Overwijk WW. Human CD4(+) T cells spontaneously detect somatic mutations in cancer cells. Nat Med. 2015;21:12–4.View ArticlePubMedGoogle Scholar
- Kloor M, Becker C, Benner A, Woerner SM, Gebert J, Ferrone S, et al. Immunoselective pressure and human leukocyte antigen class I antigen machinery defects in microsatellite unstable colorectal cancers. Cancer Res. 2005;65:6418–24.View ArticlePubMedGoogle Scholar
- Surmann EM, Voigt AY, Michel S, Bauer K, Reuschenbach M, Ferrone S, et al. Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother. 2015;64:357–66.View ArticlePubMedGoogle Scholar